Clinical Trial Update: The Vascutek Rapidax™ II Post Market Surveillance Registry

View source ↗

Summary

Update on the Vascutek Rapidax II post-market surveillance registry; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease

Drugs mentioned

• Vascutek Rapidax II

Snippet

Sponsor: Vascutek Ltd. | Conditions: End Stage Kidney Disease | Status: TERMINATED